Advertisement

Developing Therapeutic Plans for Patients with Chronic Hepatitis B or C

A Practical Approach
  • Robert Reindollar
Part of the Clinical Gastroenterology book series (CG)

Abstract

Each patient with chronic viral hepatitis has a unique medical and psychosocial history. Developing the therapeutic plan and effectively managing the patient with chronic viral hepatitis involves taking care of the entire patient, anticipating the needs and potential problems for each patient, and educating the patient regarding their disease and its management. Developing the therapeutic plan and initiating treatment for the patient with chronic viral hepatitis is best achieved with a team approach, with the patient clearly in the center of the team.

Keywords

Chronic Hepatitis Sustained Virologic Response Cirrhotic Patient HBeAg Seroconversion Chronic Viral Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis G, Lau J. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(Supp1 1): 122S–127S.CrossRefGoogle Scholar
  2. 2.
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combinatin with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–1492.PubMedCrossRefGoogle Scholar
  3. 3.
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b lus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventinal Therapy Group. Lancet 1998; 352: 1426–1432.PubMedCrossRefGoogle Scholar
  4. 4.
    Poynard T, McHutchison J, Goodman Z, et al. Is an °a la carte“ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31: 211–218.PubMedCrossRefGoogle Scholar
  5. 5.
    Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91: 309–313.PubMedGoogle Scholar
  6. 6.
    Guyer DR, Tiederman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111: 350–356.PubMedCrossRefGoogle Scholar
  7. 7.
    Chan HL, Ghany MG, Lok ASF. Hepatitis B. In: Schiff’s Diseases of the Liver (Schiff ER, Sorrell MF, Maddrey WC, eds.), vol 1,8th ed. Philadelphia: LippincottRaven, 1998, pp. 757–791.Google Scholar
  8. 8.
    Alter H. New kit on the block: evaluation of second-generation assay for detection of antibody to the hepatitis C virus. Hepatology 1992; 15: 350–353.PubMedCrossRefGoogle Scholar
  9. 9.
    Younossi Z, McHutchison J. Serologic tests for HCV infection. Viral Hepatitis Rev 1996; 2: 161–173.Google Scholar
  10. 10.
    Toyoda H, Nakano S, Kumada T, et al. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients. J Med Virol 1996; 48: 354–359.PubMedCrossRefGoogle Scholar
  11. 11.
    Simmons P. Variability of hepatitis C. Hepatology 1995; 21: 570–583.CrossRefGoogle Scholar
  12. 12.
    Bukh J, Miller PH, Purcell RH. Genetic heterogeneity of hepatitis C virus, quasispecies and genotypes. Semin Liver Dis 1995; 15: 41–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology 1997; 26(Suppl 1); 89S–95S.CrossRefGoogle Scholar
  14. 14.
    Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318–1325.PubMedGoogle Scholar
  15. 15.
    Perrillo RP, Schiff ER, Davis GL, et al. Randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Eng J Med 1990; 323: 295–301.CrossRefGoogle Scholar
  16. 16.
    Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761–763.PubMedCrossRefGoogle Scholar
  17. 17.
    National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997; 26(Suppl 1): 2S–10S.Google Scholar
  18. 18.
    Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26 (Supp1 1): 15S–20S.CrossRefGoogle Scholar
  19. 19.
    Di Bisceglie AM. Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. Am J Med 1999; 107(Suppl): 53S–55S.CrossRefGoogle Scholar
  20. 20.
    Chronic Hepatitis C: Current Disease Management, National Digestive Diseases Information Clearinghouse. Retrieved June 25, 1999 from World Wide Web: http: //ww.niddk.nih.gov/health/digest/pubs/chrnhepc.htm.Google Scholar
  21. 21.
    Yano M, Kumada H, Kage M, et al. Long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334–1340.PubMedCrossRefGoogle Scholar
  22. 22.
    Di Biceglie AM, Fong TL, Fried MW, et al. Randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993; 88: 1887–1892.Google Scholar
  23. 23.
    Fried MW. Therapy of chronic viral hepatitis. Medi Clin North Am 1996; 80: 957–972.CrossRefGoogle Scholar
  24. 24.
    Brumage LK, Wright TL. Treatment for recurrent viral hepatitis after liver transplantation. J Hepatol 1997; 26: 440–445.PubMedCrossRefGoogle Scholar
  25. 25.
    Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132: 723–731.PubMedGoogle Scholar
  26. 26.
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med 1999; 341: 1256–1263.PubMedCrossRefGoogle Scholar
  27. 27.
    Lai SL, Chien RN, Leung NW, et al. One-year trial of lamivudine for chronic hepatitis B. New Engl J Med 1998; 339: 61–68.PubMedCrossRefGoogle Scholar
  28. 28.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–832.PubMedCrossRefGoogle Scholar
  29. 29.
    Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29: 1039–1043.PubMedCrossRefGoogle Scholar
  30. 30.
    Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374–1379.PubMedGoogle Scholar
  31. 31.
    Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207–1211.PubMedCrossRefGoogle Scholar
  32. 32.
    Maddrey WC. Safety of combintin interferon alpha-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naïve patients. Semin Liver Dis 1999; 19(Suppl): 67–75.PubMedGoogle Scholar
  33. 33.
    McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for initial treatment of chronic hepatitis C. Sem Liver Dis 1999; 19(Suppl): 57–65.Google Scholar
  34. 34.
    Transplant Patient DataSource (2000, February 16). Richmond, VA: United Network for Organ Sharing. Retrieved August 15,2000 from the World Wide Web: http: //207.239.150.13/tpd/.Google Scholar
  35. 35.
    Davis GL, Albright JE, et al. Projecting the future healthcare burden from hepatitis C in the United States (abstract). Hepatology 1998; 28: 390A.Google Scholar
  36. 36.
    Heathcote EJ, Shiffman ML, et al. Multinational evaluation of the efficacy and safety of once-weekly peginterferon alpha-2a(peg-inf) in patients with chronic hepatitis C (CHC) with compensated cirrhosis (abstract). Hepatology 1999, 30: 316A.Google Scholar
  37. 37.
    Shiffman ML, Hofmann CM, Contos MJ, et al. Randomized, controlled trail of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 17: 1164–1172.CrossRefGoogle Scholar
  38. 38.
    Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up of 384 patients. Gastroenterology 1997; 112: 463–472.PubMedCrossRefGoogle Scholar
  39. 39.
    Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment redudces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; Apr 118: 655–660.Google Scholar
  40. 40.
    Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med 1999; 107(Suppl); 79S–84S.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Robert Reindollar

There are no affiliations available

Personalised recommendations